Sales: £7.99 billion
→ Exceeded analysts' expectations of £7.80 billion and was up on the previous year's figure of £7.88 billion
- Net profit: £1.44 billion
→ Significant increase compared to £1.17 billion in the previous year
- Core operating profit: £2.63 billion
→ +12% at constant exchange rates
- Adjusted earnings per share (EPS): 46.5 pence
→ Above analysts' expectations
analysts
Outlook for the full year 2025:
- GSK now expects sales growth at the upper end of the 3-5% range
- Core operating profit growth is also expected at the upper end of the 6-8% range
Encouraged by surprisingly strong quarterly figures, GSK has forecast a full-year result at the upper end of the targeted range. The most important division, Specialty Medicines, had developed very well, said Emma Walmsley, the pharmaceutical group's CEO, on Wednesday.
Drugs for the treatment of respiratory diseases, cancer, inflammation and HIV had recorded double-digit growth rates.
In the second quarter, Group sales grew by six percent in constant currency to the equivalent of a good nine billion euros. Net profit amounted to 46.5 pence per share. GSK is forecasting sales growth of three to five percent for 2025. Net profit is expected to increase by six to eight percent. This outlook already takes into account the US tariffs, it said.
GSK shares were nevertheless unable to maintain their opening gains on the London Stock Exchange and lost around half a percent.
Some analysts will probably have to revise their forecasts downwards due to the expected negative impact of exchange rate effects, commented analyst Benjamin Jackson from investment bank Jefferies.